Lei Li

On May 24, 2017, the China Food and Drug Administration (CFDA) issued its [2017] Circular No. 63 (the Circular), setting out penalties for clinical trial data integrity violations, including intentional data falsification, incomplete and incompliant data and other data defects. The highlights are: (more…)